Skip to main content

Table 4 Study Endpoints

From: A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)

Systemic effects
 - Glucose metabolism (fasting glucose, 2 h glucose, insulin, hemoglobin a1c, HOMA-index)
 - Cholesterol (high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, total cholesterol)
 - Inflammatory markers (interleukin 1-β, interleukin-6, interleukin-8, tumour necrotic factor-alpha)
 - Adipocytokines (adiponectin, leptin)
 - Reproductive hormones (total testosterone, free testosterone, luteinizing hormone)
Body composition and bone mineral density
 - Whole body bone mineral density, whole body t-score, t-score of the lumbar spine and proximal femoral bone
 - Lean body mass
 - Whole body fat percent (Z-score)
 - Visceral adiposity, android fat distribution, gynoid fat distribution
Anthropomorphic measures
 - Waist circumference
 - Hip circumference
 - Body mass index
 - Anogenital distance
Patient reported outcomes
 - Health related quality of Life (EORTC QLQ-C30)
 - Anxiety and Depression: (Hospital Depression and Anxiety Scale)
 - Fatigue: (Multiple Fatigue Inventory-20)
 - Symptoms of testosterone deficiency and erectile dysfunction: (International Index of Erectile Function-15)
  1. Abbreviations: HOMA-index Homeostasis model assessment index, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire